Evidence map›Paper›PMID 34093531›Full record

Trial reportFrontiers in immunology2021

Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia.

Marcel Doerflinger, Gabrielle M Haeusler, Connie S N Li-Wai-Suen, Julia E Clark, Monica Slavin, Franz E Babl, Zoe Allaway, Francoise Mechinaud, Gordon K Smyth, Richard De Abreu Lourenco and 3 more

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter StudyValidation Study
In one paragraph

Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06383338 (A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06383338 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.

TypeinterventionalSponsorMurdoch Childrens Research InstituteRan2025 to 2026Enrolled10ConditionsHodgkin Lymphoma, Non Hodgkin LymphomaArmsOmeprazole, Dextromethorphan
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Procalcitonin in Pediatric Sepsis: What Is It Good for?Journal of the Pediatric Infectious Diseases Society · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Marcel DoerflingerInfectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute for Medical Research, Parkville, VIC, Australia.
Gabrielle M HaeuslerDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Connie S N Li-Wai-SuenInfectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute for Medical Research, Parkville, VIC, Australia.
Julia E ClarkQueensland Children's Hospital, Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia.
Monica SlavinDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Franz E BablInfection and Immunity Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Zoe AllawayDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Francoise MechinaudUnité D'hématologie Immunologie Pédiatrique, Hopital Robert Debré, APHP Nord Université de Paris, Paris, France.
Gordon K SmythInfectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute for Medical Research, Parkville, VIC, Australia.
Richard De Abreu LourencoCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia.
Bob PhillipsLeeds Children's Hospital, Leeds General Infirmary, Leeds, United Kingdom.
Marc PellegriniInfectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute for Medical Research, Parkville, VIC, Australia.
Karin A ThurskyDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
University of Melbourne · AUNational Health and Medical Research Council · AUVictorian Comprehensive Cancer Centre · AUAssistance Publique – Hôpitaux de Paris · FRLeeds General Infirmary · GBUniversity of Queensland · AUUniversity of Technology Sydney · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

Medical Research Council G0800472
6 · The paper itself

Abstract

Objectives: Febrile neutropenia (FN) causes treatment disruption and unplanned hospitalization in children with cancer. Serum biomarkers are infrequently used to stratify these patients into high or low risk for serious infection. This study investigated plasma abundance of cytokines in children with FN and their ability to predict bacteraemia. Methods: Thirty-three plasma cytokines, C-reactive protein (CRP) and procalcitonin (PCT) were measured using ELISA assays in samples taken at FN presentation (n = 79) and within 8-24 h (Day 2; n = 31). Optimal thresholds for prediction of bacteraemia were identified and the predictive ability of biomarkers in addition to routinely available clinical variables was assessed. Results: The median age of included FN episodes was 6.0 years and eight (10%) had a bacteraemia. On presentation, elevated PCT, IL-10 and Mip1-beta were significantly associated with bacteraemia, while CRP, IL-6 and IL-8 were not. The combination of PCT (≥0.425 ng/ml) and IL-10 (≥4.37 pg/ml) had a sensitivity of 100% (95% CI 68.8-100%) and specificity of 89% (95% CI 80.0-95.0%) for prediction of bacteraemia, correctly identifying all eight bacteraemia episodes and classifying 16 FN episodes as high-risk. There was limited additive benefit of incorporating clinical variables to this model. On Day 2, there was an 11-fold increase in PCT in episodes with a bacteraemia which was significantly higher than that observed in the non-bacteraemia episodes. Conclusion: Elevated PCT and IL-10 accurately identified all bacteraemia episodes in our FN cohort and may enhance the early risk stratification process in this population. Prospective validation and implementation is required to determine the impact on health service utilisation.

Indexed as

BacteremiaChildChild, PreschoolFebrile NeutropeniaFemaleHumansInterleukin-10MaleNeoplasmsPredictive Value of TestsProcalcitoninIL10 protein, humanInterleukin-10Procalcitoninbiomarkerscancerchildrenfebrile neutropeniarisk stratification

Identifiers

PMID34093531
PMCPMC8173204
OpenAlexW3163203027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.